Department of Pediatrics, Roswell Park Comprehensive Cancer Center., Buffalo, NY.
Division of Pediatric Hematology/Oncology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.
J Clin Oncol. 2024 Feb 20;42(6):653-664. doi: 10.1200/JCO.23.01799. Epub 2023 Nov 20.
Hodgkin lymphoma (HL) represents one of the more common cancers occurring in adolescent and young adults (AYAs) age 15-39 years. Despite a generally high cure rate, age-related differences in HL biology and the optimal therapeutic approaches including supportive care and risks for long-term adverse effects in the AYA population remain understudied. After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches. Recently completed and ongoing studies will foster harmonization of risk group definition and trial eligibility criteria across the AYA spectrum, enabling more rapid progress. In addition to treatment approaches, an evolving holistic care approach to AYA HL will result in enhanced understanding of unique challenges, and continued improved short- and long-term outcome for these patients.
霍奇金淋巴瘤（HL）是青少年和年轻成年人（AYAs）15-39 岁时较为常见的癌症之一。尽管总体治愈率较高，但与年龄相关的 HL 生物学差异以及包括支持性护理在内的最佳治疗方法，以及 AYA 人群中长期不良影响的风险仍研究不足。在概述了 AYA 人群中的 HL 流行病学和生物学之后，本综述将涵盖一线儿科和成人治疗方法。最近完成和正在进行的研究将促进在 AYA 范围内协调风险组定义和试验资格标准，从而实现更快的进展。除了治疗方法外，对 AYA HL 的整体治疗方法的不断发展将有助于更好地了解独特的挑战，并为这些患者持续改善短期和长期结果。
